CDA isolated nine markers that together differentiated between those who developed cirrhosis vs. controls; these markers included HGF and SLAMF1, as well as angiogenin (ANG), insulin-like growth factor-binding protein 3 (IGFBP3), plasma serine protease inhibitor (SERPINA5), eotaxin (CCL11), two C-X-C motif chemokines (CXCL11 and CXCL9), and STAM-binding protein (STAMBP). This evidence concerns the gene CXCL9 and Cirrhosis.